Evolving treatment paradigms for chemotherapy-induced nausea and vomiting

Cancer Control

Volumn 19, Issue 2 SUPPL., 2012, Pages 3-9

  Wickham, Rita ^a  

^a University School of Nursing   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOPAMINE; FLUOROURACIL; FOSAPREPITANT; GRANISETRON; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROTRANSMITTER; OLANZAPINE; ONDANSETRON; PALONOSETRON; PLACEBO; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST;

ACNE; ACUPRESSURE; ADVANCED CANCER; AGITATION; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY; APPETITE; ASTHENIA; BRADYCARDIA; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONGESTIVE HEART FAILURE; CONSTIPATION; COST CONTROL; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEART ARREST; HEART ARRHYTHMIA; HICCUP; HIGHLY EMETOGENIC CHEMOTHERAPY; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INCREASED APPETITE; INSOMNIA; INTESTINE INNERVATION; LEUKOPENIA; LOW DRUG DOSE; MENTAL INSTABILITY; MODERATELY EMETOGENIC CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PEPTIC ULCER; PR PROLONGATION; PRURITUS; PSYCHOSIS; QT PROLONGATION; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STEROID PSYCHOSIS; STEVENS JOHNSON SYNDROME; STOMACH CANCER; TACHYCARDIA; TASTE; THROMBOCYTOPENIA; TORSADE DES POINTES; TREATMENT PLANNING; URINE RETENTION; VOMITING; WEIGHT GAIN;

EID: 84859447896     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201902s02     Document Type: Review

References (57)

1. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapyinduced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5):497-503.
2. Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapyinduced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer. 2011;19(6):843-851.
3. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472-4478.
4. Ballatori E, Roila F, Ruggeri B, et al. The impact of chemotherapyinduced nausea and vomiting on health-related quality of life. Support Care Cancer. 2007;15(2):179-185.
5. Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20(1):107-117.
6. Borison HL, Wang SC. Functional localization of central coordinating mechanism for emesis in cat. J Neurophysiol. 1949;12(5):305-313.
7. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev. 1953;5(2):193-230.
8. Borison HL, Borison R, McCarthy LE. Phylogenic and neurologic aspects of the vomiting process. J Clin Pharmacol. 1981;21(8-9 suppl):23S-29S.
9. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-2494.
10. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14(2):85-93.
11. Frame DG. Best practice management of CINV in oncology patients: I. physiology and treatment of CINV: multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol. 2010;8(2 suppl 1):5-9.
12. Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003; 39(8):1074-1080.
13. Darmani NA, Crim JL, Janoyan JJ, Abad J, Ramirez J. A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res. 2009;1248:40-58.
14. Darmani NA, Chebolu S, Amos B, Alkam T. Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav. 2011;99(4):573-579.
15. Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010;335(2):362-368.
16. Gershon MD. Review article: serotonin receptors and transporters- roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. 2004;20(suppl 7):3-14.
17. Blackshaw LA, Brookes SJ, Grundy D, Schemann M. Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil. 2007;19(suppl1): 1-19.
18. Burke CW, Mason JN, Surman SL, et al. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog. 2011;7(7):e1002134.
19. Lesurtel M, Soll C, Graf R, Clavien PA. Role of serotonin in the hepatogastrointestinal tract: an old molecule for new perspectives. Cell Mol Life Sci. 2008;65(6):940-952.
20. Färber L, Haus U, Späth M, Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl. 2004;119:2-8.
21. Endo T, Hamaue N, Ihira E, et al. Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model. Res Comm Mol Pathol Pharmacol. 2002;111(1-4):55-68.
22. Cabezos PA, Vera G, Martin-Fontelles MI, Fernández-Pujol R, Abalo R. Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat: comparison with pica. Neurogastroenterol Motil. 2010:22(7):797-805, e224-e225.
23. Diemunsch P, Grélot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60(3):533-546.
24. Huskey SE, Dean BJ, Bakhtiar R, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos. 2003;31(6):785-791.
25. Moertel CG, Reitemeier RJ, Gage RP. A controlled clinical evaluation of antiemetic drugs. JAMA. 1963;186:116-118.
26. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198.
27. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 1.2012. National Comprehensive Cancer Network. http://www.nccn.org. Accessed February 22, 2012.
28. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232-v243.
29. Roscoe JA, Bushunow P, Morrow GR, et al. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer. 2004;101(11):2701-2708.
30. Fiore JJ, Gralla RJ. Pharmacologic treatment of chemotherapy-induced nausea and vomiting. Cancer Invest. 1984;2(5):351-361.
31. De Mulder PH, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin- induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990;113(11):834-840.
32. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011;22(1):30-38.
33. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007;15(9):1023-1033.
34. de Wit R, Aapro M, Blower PR. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? Cancer Chemother Pharmacol. 2005;56(3):231-238.
35. Wong EH, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995;114(4):851-859.
36. Rubenstein EB. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2004(5);2:284-289.
37. Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegovetti B. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2011;19(6):823-832.
38. Likun Z, Xiang J, Yi B, Xin D, Tao ZL. A systematic review and metaanalysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist. 2011;16(2):207-216.
39. Epocrates. http://www.epocrates.com/online. Accessed March 2, 2012.
40. Drugstore.com. http://www.drugstore.com. Accessed March 2, 2012.
41. Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol. 2006;4(1): 35-41, 52.
42. Duggan ST, Curran MP. Transdermal granisetron. Drugs. 2009;69 (18):2597-2605.
43. Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. 2009;15(4):223-231.
44. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. 2000;18(19):3409-3422.
45. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18(2):233-240.
46. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97(9):2290-2300.
47. Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18(9):1171-1177.
48. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol. 2011;29(11):1495-1501.
49. Lindley C, Goodin S, McCune J, et al. Prevention of delayed chemotherapy- induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol. 2005;28(3):270-276.
50. Jones JM, Qin R, Bardia A, Linquist B, Wolf S, Loprinzi CL. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med. 2011;14(7):810-814.
51. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapyinduced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15(11):1285-1291.
52. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188-195.
53. Ramsey SD, Fedorenko CR, Snell KS, et al. Cancer diagnosis as a risk factor for personal bankruptcy. ASCO Annual Meeting Abstracts. 2011;29:6007.
54. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19(1):131-140.
55. Molassiotis A, Helin AM, Dabbour R, Hummerston S. The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. Complement Ther Med. 2007;15(1):3-12.
56. Ryan JL, Heckler CE, Roscoe JA, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2011 Aug 5. Epub ahead of print.
57. Zick SM, Ruffin MT, Lee J, et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer. 2009;17(5):563-572.